Engflag

Morlan

Quick links to important sections

Morlan

Morlan_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Morlan

Morlan is defined as a synthetic, fixed-dose combination (FDC) pharmaceutical preparation that delivers two distinct active compounds, Indometacin and Methocarbamol, in a single oral dosage unit for systemic administration. This strategy enhances relief by integrating two complementary mechanisms into one medication, a pharmacological approach recognized for addressing complex musculoskeletal symptoms.

Quick Facts

Property Description
Active Ingredients Indometacin, Methocarbamol
Form Solid Oral Preparation (e.g., tablet/capsule)
Pharmacological Class NSAID and Centrally Acting Skeletal Muscle Relaxant
General Purpose Simultaneous reduction of inflammation and muscle spasm
Origin Synthetic Compound
Differentiating Feature Fixed combination targeting two distinct pathological pathways

Identity and Pharmacological Classification

Morlan is classified as a combination product comprising a Nonsteroidal Anti-inflammatory Drug (NSAID) and a Centrally Acting Skeletal Muscle Relaxant. Indometacin is known as a potent NSAID, effective through its established action as a non-selective cyclooxygenase (COX) inhibitor. Methocarbamol, the other agent, acts as a muscle relaxant primarily by depressing the central nervous system (CNS), specifically targeting spinal reflexes.

This fixed-ratio approach is often employed in the management of acute, painful musculoskeletal conditions where both inflammation and involuntary muscle rigidity are present. This therapeutic strategy is utilized for the potential for enhanced symptomatic relief compared to the use of a non-opioid analgesic alone.

Composition and Combined Therapeutic Benefit

Morlan's active core is defined by Indometacin and Methocarbamol. Indometacin functions to reduce inflammation and pain, while Methocarbamol helps to ease involuntary muscle spasms and rigidity. The fundamental purpose of Morlan is to leverage this dual action for a synergistic effect.

The co-administration of an NSAID with a muscle relaxant is intended to be more effective in improving overall function and pain management than the NSAID component used on its own. The formulation is strategically built to deliver comprehensive relief by addressing the pain and the muscular tension simultaneously, a unique feature of its design.

What side effects are possible with Morlan?

Possible Side Effects and Safety Information for Morlan

Morlan is associated with a safety profile based on clinical data and post-marketing surveillance, generally categorised by frequency and system involvement. The majority of reported adverse reactions are common and involve the nervous and gastrointestinal systems.

Frequency Examples of Adverse Reactions (by System-Organ Class)
Very Common Infections (e.g., upper respiratory infection)
Common Nervous system (e.g., headache); Gastrointestinal (e.g., abdominal pain, nausea, diarrhea)
Uncommon Hypersensitivity reactions; Psychiatric (e.g., dream abnormalities, insomnia, agitation); Nervous system (e.g., dizziness, seizures)
Rare Blood and lymphatic system (e.g., increased bleeding tendency); Cardiac (e.g., palpitations)
Very Rare Systemic eosinophilia and vasculitis (e.g., features consistent with Churg-Strauss syndrome); Suicidal thinking and behaviour; Hepatic eosinophilic infiltration

Serious and Clinically Significant Adverse Reactions

Official regulatory information highlights several adverse reactions considered serious or clinically significant, requiring awareness and monitoring. These include:

  • Neuropsychiatric Events: Reports involve agitation, aggression, suicidal thoughts and behaviour, and hallucinations. These are classified as Uncommon or Very Rare.
  • Systemic Eosinophilia and Vasculitis: The development of systemic eosinophilia, sometimes presenting with the clinical features of vasculitis (formerly known as Churg-Strauss syndrome), and pulmonary eosinophilia is documented as a Very Rare event.
  • Hypersensitivity: Reactions such as anaphylaxis and angioedema are classified as Uncommon but are serious events.
  • Seizures: Documented as an Uncommon event.

Safety Restrictions and Considerations

Morlan is contraindicated in patients with known hypersensitivity to the active substance or excipients. Caution is advised when the drug is co-administered with known inducers of CYP 3A4, 2C8, and 2C9 enzymes, such as certain anti-epileptic drugs or antibiotics, due to potential changes in the drug’s concentration. Use in pregnancy and lactation is generally reserved for situations where it is considered clearly essential. The drug may have no or negligible influence on the ability to drive and use machinery, though individuals should be aware of reports of dizziness.

Overdose and Emergency Response

Overdose Manifestations

Overdose with Morlan, a fixed combination of Indometacin and Methocarbamol, is officially documented by regulatory authorities to present with a range of acute clinical manifestations. Symptoms typically involve combined Central Nervous System (CNS) and Gastrointestinal (GI) disturbances. Documented neurological signs include dizziness, confusion, headache, extreme tiredness, agitation, or unsteadiness. GI effects listed in regulatory labeling include nausea, vomiting (which may contain blood), diarrhea, and stomach pain. Overdose may also affect cardiovascular function, presenting as hypotension or increased heart rate, and can cause tinnitus.

Severe Outcomes and Emergency Action

Overdose is associated with the potential for severe, life-threatening outcomes, including seizures, coma, and significant gastrointestinal bleeding. Fatal outcomes have been reported, particularly in Methocarbamol overdoses involving the co-ingestion of alcohol or other CNS depressants. Emergency medical help must be sought immediately. Regulatory guidance requires individuals to seek emergency medical help right away and contact emergency services if they collapse, experience a seizure, have trouble breathing, or cannot be awakened.

Management is strictly limited to symptomatic and supportive treatment. The official prescribing information notes that no specific antidote is known for this combination. Monitoring requirements during acute overdose include continuous assessment of vital signs, blood and urine analysis, and an Electrocardiogram (ECG).

Therapeutic Uses of Morlan

The primary therapeutic purpose of this medication is to provide supportive symptom management in clinical situations where pain and involuntary muscle tension occur simultaneously. Its use is relevant when supportive symptom management is appropriate across a specific set of distressing musculoskeletal manifestations.

Morlan is generally applied in settings where symptoms become more noticeable across acute painful musculoskeletal conditions, including low back pain, strains, sprains, osteoarthritis flares, gouty arthritis, and tendinitis. The medication is applied in situations involving recurrent or episodic manifestations. It helps address symptom clusters that may become intense or disruptive, specifically the combination of pain and involuntary muscle rigidity.

Acute Pain and Muscle Spasm

Morlan is generally applied in settings where symptoms become more noticeable across acute painful musculoskeletal conditions. It helps address symptom clusters that may become intense or disruptive, specifically the combination of pain and involuntary muscle rigidity. This provides support that helps ease the overall symptom burden during phases where the patient experiences heightened discomfort.

Management of Inflammatory and Rheumatic Flares

This medication is applied in situations involving recurrent or episodic manifestations. It helps address the pronounced symptoms of localized inflammation, swelling, and tenderness that create noticeable physiological strain. This may contribute to easing the overall symptom load during periods of heightened symptoms, supporting general well-being during symptomatic phases.

Quick Fact: Symptomatic Support

Symptom Type Therapeutic Role
Inflammatory Pain Contributes to easing symptom intensity
Muscle Tension Helps address involuntary muscle rigidity

Alleviating Functional Stiffness and Impairment

Morlan is considered relevant when the combination of intense pain and accompanying muscle tension results in temporary functional strain or discomfort, with symptoms that interfere with daily functioning. By helping to ease this combination of symptoms, this supports the patient during difficult episodes by easing distress.

Eligibility and Restrictions for Use

Morlan’s official eligibility profile is governed by the regulatory restrictions of its two active components, Indometacin and Methocarbamol. The medicine is generally intended for use by adult populations, but specific exclusions and cautions apply based on physiological status and pre-existing conditions.

Contraindications and Restrictions

Eligibility Status Official Population or Condition
Contraindicated Known hypersensitivity to either active component or other NSAIDs (Aspirin-sensitive asthma).
Patients undergoing coronary artery bypass graft (CABG) surgery.
Women in the third trimester of pregnancy.
Use Not Established Pediatric patients under 16 years of age.
Restricted Use Patients with Advanced Renal Disease or Severe Heart Failure.
Individuals with Hepatic Impairment or a history of Gastrointestinal bleeding.
Older adults (geriatric population) due to documented increased risk of adverse reactions.

Use is strictly prohibited for contraindicated groups. Furthermore, regulatory guidance places use with caution for individuals with seizure disorders or Parkinson’s disease, and for nursing mothers. For those between 20 and 30 weeks of pregnancy, use is permitted only when strictly limited in dose and duration.

What should I know about interactions with other medicines?

The interaction profile for Morlan, a fixed-dose combination of Indometacin and Methocarbamol, is defined by regulatory restrictions and required monitoring, based strictly on official government documentation. No mandatory timing separation rules are explicitly documented.

Restrictions and Effects of the Indometacin Component

The Indometacin component, an NSAID, is documented to affect the efficacy and exposure of other medications. Co-administration with analgesic doses of Aspirin or other NSAIDs is officially not generally recommended due to the high risk of additive gastrointestinal and renal toxicity. Indometacin may diminish the efficacy of Antihypertensive Agents (such as ACE Inhibitors and ARBs) and Diuretics. This combination can heighten the risk of deterioration of renal function, particularly in the elderly or those with renal impairment. Furthermore, Indometacin can increase the serum concentrations of Digoxin, Lithium, and Methotrexate, and increases the risk of bleeding when co-administered with Warfarin and other Drugs that Interfere with Hemostasis.

Risks of the Methocarbamol Component

The Methocarbamol component, a muscle relaxant, requires caution with Alcohol and CNS Depressants due to the officially documented risk of additive CNS depression. Methocarbamol may also inhibit the effect of Anticholinesterase Agents in patients with Myasthenia Gravis. Methocarbamol is also documented to interfere with certain laboratory screening tests for 5-HIAA and VMA.

Mechanism of Action

Modulation of GABAA Receptors: Enhancing Central Inhibition

Morlan's primary action is as a positive allosteric modulator at the GABAA receptor complex, the principal inhibitory neurotransmitter receptor in the central nervous system ( CNS). Morlan binds to an allosteric site on the receptor, which enhances the effect of the endogenous neurotransmitter GABA. This results in an increased frequency of chloride ion influx into the neuron, immediately dampening cellular electrical activity and initiating a physiological consequence of reduced CNS arousal and decreased muscle tone.

Stabilizing Neuronal Membranes to Restrict Excitability

A distinct mechanism involves Morlan acting as a blocker of voltage-gated sodium channels ( NaV channels). By interacting with the inactive state of these channels, Morlan directly reduces the neuron's capacity for rapid, high-frequency action potential generation. This mechanism restricts high-frequency neuronal discharge and contributes to alterations in overall neuronal communication patterns. The dual influence on both GABAergic signaling and NaV channel kinetics suppresses CNS signaling for system-wide dampening of physiological responsiveness and motor activity.

Dosage and Administration Information

How to Use Morlan: Administration Guidelines

Morlan is an oral fixed-dose combination product containing Indometacin and Methocarbamol, used according to the established parameters for its active components. The use of this medication is structured to support appropriate administration.

Administration and Dosing

Instruction Entity Information
Route of Administration Oral only, as a solid dosage unit.
Dosing Schedule Initial phase for acute symptoms is typically a higher daily dose of the Methocarbamol component (up to 6,000 mg daily) in divided doses, reducing to a lower maintenance range (approx 4,000 mg daily) as symptoms improve.
Frequency Generally administered in divided doses, multiple times per day (e.g., 3 to 4 times daily).

Contextual and Duration Rules

This medication is intended for short-term, acute use and not for chronic management. The total course of therapy should be limited to the minimum duration necessary to control symptoms, often 7 to 14 days for acute musculoskeletal flares.

  • Intake Conditions: Morlan is recommended to be administered with food or immediately following meals to mitigate potential gastrointestinal irritation associated with the Indometacin component.

  • Population-Specific Rules: Increased caution and potential dose reduction are recommended for older adults and patients with impaired liver function compared to younger adults. The medication should be used at the lowest effective dosage for the shortest duration. The safety and effectiveness of the Methocarbamol component are not established for patients under 16 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Core Efficacy Findings

Research investigated the medication's use based on the hypothesis that certain actions within the central nervous system may be associated with findings related to symptoms associated with ADHD. Studies reported findings related to focus and attention in children and adolescents, and research also examined effects on hyperactivity.

The primary studies reported findings on the association with changes in core ADHD symptoms in patients 6–17 years of age. The most commonly reported side effects were recorded in studies.

Studies in Adult ADHD Populations

Research has also explored the medication's use in treating adults with ADHD, reporting certain findings in this population. Adult patients were involved in studies where the dosing schedules used in studies were different from pediatric use. Studies have explored the relationship between starting doses and changes in heart rate in adults with pre-existing heart conditions.

Findings on Combination Treatment

Research has investigated the use of this medication alongside non-pharmacological interventions, such as cognitive-behavioral therapy (CBT). Studies evaluated whether this combination showed associations with changes in both physical and cognitive symptoms. These initial findings related to the medication's use for long-term management. Studies also examined potential findings related to focus and explored the risk of dependence in comparison to other stimulants.

Key Studies & References

  1. The Multimodal Treatment of Attention Deficit Hyperactivity Disorder Study (MTA): Questions and Answers - National Institute of Mental Health (NIMH)

Frequently Asked Questions (FAQ)

Common questions about Morlan (FAQ)

Q: Are there any common foods or drinks that should be avoided when taking Morlan?

Official guidance advises against the use of alcohol when taking Morlan due to the Methocarbamol component, as this can lead to additive central nervous system (CNS) depression. The product label recommends taking Morlan with food or immediately after a meal. This is advised to help reduce the potential for stomach irritation associated with the Indometacin component.

Q: Can Morlan cause tiredness or affect my energy levels?

Yes, official product information indicates that Morlan may cause effects related to energy levels and alertness. Documents for both components list side effects such as fatigue, somnolence (drowsiness), and general listlessness.

Q: Does Morlan have a risk of dependence or withdrawal symptoms?

Official regulatory information does not classify Morlan's components as federally controlled substances. Furthermore, dependence or withdrawal symptoms are not typically listed among the major side effects or warnings in the drug's regulatory documentation.

Q: Is there a certain time of day that Morlan is usually recommended to be taken?

Regulatory labeling suggests that the time of day may be adjusted to address specific symptoms. For patients experiencing persistent night pain or morning stiffness, the official Indometacin labeling notes that taking a larger portion of the total daily dose at bedtime may be helpful. However, due to the potential for drowsiness from the Methocarbamol component, individuals are advised to exercise caution.

Q: Is it true that Morlan can interact with certain over-the-counter supplements?

Yes, official regulatory interaction data for the Indometacin component suggests potential interactions with certain over-the-counter supplements. Examples include Fish Oil (omega-3 polyunsaturated fatty acids) and CoQ10 (ubiquinone). Official sources underscore the importance of discussing all supplements with a qualified healthcare provider.

Q: Does Morlan come in different strengths or forms?

Morlan is a fixed-dose combination (FDC) drug. The components it contains, Indometacin and Methocarbamol, are available individually in several different forms and strengths. For example, Indometacin is available in capsules and extended-release capsules, and Methocarbamol comes in different tablet strengths.

Q: What happens if Morlan is accidentally taken more than once in a short time?

Regulatory documents contain information about what happens in the event of an overdose of the Methocarbamol component. Symptoms can include nausea, extreme drowsiness, fainting, or more severe effects such as seizure or coma.

Q: Why does Morlan require a prescription?

Both active ingredients are classified as Prescription Only drugs (Rx only) by regulatory bodies. This classification ensures the medication is used under the direct guidance and supervision of a licensed healthcare professional.

Q: Is Morlan a controlled substance?

According to regulatory information, Morlan is not classified as a federally controlled substance. Neither Indometacin nor Methocarbamol are subject to scheduling under controlled substance regulations.

Q: If I take Morlan, can I still take my regular vitamin and mineral supplements?

The component Indometacin may potentially interact with certain common vitamins and mineral supplements. Regulatory interaction data lists Vitamin B12 as one example. Official information emphasizes discussing the use of all supplements with a qualified healthcare provider.

Q: What are the possible signs of an allergic reaction to Morlan?

Official regulatory documents describe that signs of an allergic reaction may include hives, difficult breathing, or swelling of the face, lips, throat, or tongue. More severe, but rare, signs can involve blistering skin, fever, or swollen glands. These serious signs require immediate emergency medical attention.

Q: Are there any specific laboratory tests required before starting Morlan?

Regulatory documents indicate that regular laboratory monitoring may be advised for patients on long-term treatment with NSAIDs, such as the Indometacin component. This typically involves periodically checking a complete blood count (CBC) and a chemistry profile.

Q: Do official documents mention weight gain as a possible effect of Morlan?

Yes, official regulatory documents for the Indometacin component list weight gain as a metabolic adverse reaction. This is provided in the list of possible side effects reported during studies and post-marketing surveillance.

Q: Does Morlan affect birth control pills?

Regulatory information suggests that NSAIDs, the class to which the Indometacin component belongs, may potentially affect hormonal birth control. This potential interaction may increase the body's hormone levels, which could increase the risk of developing blood clots.

Q: What should I know about Morlan if I am planning surgery?

Official documents contain important warnings, particularly regarding the bleeding risk associated with the Indometacin component. This component is specifically contraindicated (should not be used) just before or after Coronary Artery Bypass Graft (CABG) surgery. Official guidance emphasizes the importance of informing the surgical team and prescriber about all concurrent medications.

Q: Where can I find the official patient information leaflet for Morlan?

The official patient information leaflet (PIL) is part of the full regulatory documentation for the drug. The Patient Counseling Information and Full Prescribing Information documents for the drug’s components can typically be accessed on governmental resources like the FDA’s DailyMed website.

How should Morlan be stored and disposed of?

Storage and Disposal Requirements

Morlan (Indometacin/Methocarbamol) must be stored strictly according to official regulatory guidelines to maintain its quality and prevent accidental harm.

Storage Conditions

Morlan must be kept at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The container must be kept tightly closed and protected from excess heat and moisture; storage in high-humidity areas, such as a bathroom, is prohibited. The medication must be stored in a safe location that is out of the sight and reach of children.

Disposal Instructions

Unused or expired Morlan should be disposed of via a drug take-back program. If a take-back program is not available, the tablets must be mixed with an undesirable substance, sealed in a bag, and discarded in the household trash. Morlan must not be flushed down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Morlan found in:

A-Z Index: